• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹腔镜间隔减瘤术治疗晚期卵巢癌的生存结局与开腹手术相似:一项倾向评分匹配研究。

Complete Laparoscopic Interval Debulking Surgery for Advanced Ovarian Cancer Achieves Similar Survival Outcomes to Open Approach: A Propensity-Matched Study.

机构信息

Department of Gynecologic Surgery, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

IHU-Strasbourg (Institut Hospitalo-Universitaire), Strasbourg, France.

出版信息

J Invest Surg. 2022 Jun;35(6):1394-1401. doi: 10.1080/08941939.2022.2045396. Epub 2022 Mar 1.

DOI:10.1080/08941939.2022.2045396
PMID:35227150
Abstract

To assess the laparoscopic interval debulking surgery (IDS) outcomes compared to laparotomy, by analyzing the overall survival (OS) and the progression free survival (PFS), as well as the intra- and post-operative morbidity. In this retrospective propensity-score-matched cohort study, all patients with stage III or IV FIGO (International Federation of Gynecology and Obstetrics) serous ovarian cancer, undergoing complete IDS after neoadjuvant chemotherapy, from January 1st of 2009 to June 1st 2019, were included. Thirty-seven patients were included in the laparoscopy group and 40 in the laparotomy group. There was no significant difference in terms of median OS between laparoscopy and laparotomy (23.1 months [95% CI 15.7-29.7] versus 26.3 months [95% CI 21.7-31.7], respectively,  = 0.17) and median PFS (14.8 months [95% CI 10.6-21.5] versus 12 months [95% CI 11-15.1],  = 0.057). After applying the propensity score, 25 patients were included in each group. Laparoscopy was associated with significantly less early postoperative complications (6 versus 17,  = 0.01) and shorter hospital stay (7.6 days versus 12.1,  < 0.001) and a significantly better OS (HR 0.45 [95% CI 0.19-0.95],  = 0.04), but with no significant difference in terms of PFS (HR 0.71 [95% CI 0.27-1.88],  = 0.49). In carefully-selected patients with advanced ovarian cancer, complete laparoscopic interval debulking surgery achieves similar survival outcomes to open laparotomy. Therefore, laparoscopy appears as a safe alternative to laparotomy for IDS after NACT in selected patients with advanced ovarian cancer and a low burden of disease.

摘要

为了评估与开腹手术相比,腹腔镜间隔减瘤术(IDS)的结果,通过分析总生存期(OS)和无进展生存期(PFS),以及围手术期发病率。在这项回顾性倾向评分匹配队列研究中,所有接受新辅助化疗后完全 IDS 的 III 期或 IV 期国际妇产科联合会(FIGO)浆液性卵巢癌患者均被纳入研究。从 2009 年 1 月 1 日至 2019 年 6 月 1 日,共有 37 例患者纳入腹腔镜组,40 例患者纳入开腹组。腹腔镜组和开腹组的中位 OS 无显著差异(分别为 23.1 个月[95%CI 15.7-29.7]和 26.3 个月[95%CI 21.7-31.7],  = 0.17)和中位 PFS(14.8 个月[95%CI 10.6-21.5]和 12 个月[95%CI 11-15.1],  = 0.057)。应用倾向评分后,每组纳入 25 例患者。腹腔镜手术与术后早期并发症显著减少(6 例与 17 例,  = 0.01)和住院时间缩短(7.6 天与 12.1 天,  < 0.001)和显著改善 OS(HR 0.45[95%CI 0.19-0.95],  = 0.04)有关,但 PFS 无显著差异(HR 0.71[95%CI 0.27-1.88],  = 0.49)。在精心挑选的晚期卵巢癌患者中,完全腹腔镜间隔减瘤术的生存结果与开腹手术相似。因此,对于晚期卵巢癌且疾病负担较低的患者,在新辅助化疗后,腹腔镜 IDS 似乎是开腹手术的一种安全替代方案。

相似文献

1
Complete Laparoscopic Interval Debulking Surgery for Advanced Ovarian Cancer Achieves Similar Survival Outcomes to Open Approach: A Propensity-Matched Study.腹腔镜间隔减瘤术治疗晚期卵巢癌的生存结局与开腹手术相似:一项倾向评分匹配研究。
J Invest Surg. 2022 Jun;35(6):1394-1401. doi: 10.1080/08941939.2022.2045396. Epub 2022 Mar 1.
2
Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.高级别晚期卵巢癌的初次肿瘤细胞减灭术与初次新辅助化疗:生存比较。
Radiol Oncol. 2018 Sep 11;52(3):307-319. doi: 10.2478/raon-2018-0030.
3
Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study.新辅助化疗后间隔减瘤手术治疗晚期上皮性卵巢癌:GOTIC-019 研究。
Int J Clin Oncol. 2023 Jun;28(6):804-815. doi: 10.1007/s10147-023-02329-7. Epub 2023 May 4.
4
Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.比较接受新辅助化疗的晚期上皮性卵巢癌患者的剖腹手术与机器人辅助间隔减瘤术。
J Minim Invasive Gynecol. 2021 Jun;28(6):1237-1243. doi: 10.1016/j.jmig.2020.11.015. Epub 2020 Nov 26.
5
Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.在晚期上皮性卵巢癌中,初次肿瘤细胞减灭术时的微小残留病灶与间隔性肿瘤细胞减灭术时的完全肿瘤切除相比:一项生存分析。
Gynecol Oncol. 2020 Apr;157(1):209-213. doi: 10.1016/j.ygyno.2020.01.010. Epub 2020 Jan 15.
6
[Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].[晚期卵巢癌患者新辅助化疗后行间隔减瘤手术的预后获益相关因素分析]
Zhonghua Fu Chan Ke Za Zhi. 2021 Jun 25;56(6):385-392. doi: 10.3760/cma.j.cn112141-20201207-00871.
7
Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.前瞻性手术与新辅助化疗后间隔减瘤手术治疗 IIIC 期和 IV 期卵巢癌患者的研究,SGOG SUNNY(SOC-2)试验方案。
J Gynecol Oncol. 2020 Sep;31(5):e86. doi: 10.3802/jgo.2020.31.e86.
8
Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.新辅助化疗后晚期卵巢癌的微创间隔减瘤术。
Gynecol Oncol. 2023 May;172:130-137. doi: 10.1016/j.ygyno.2023.01.017. Epub 2023 Mar 26.
9
A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.晚期卵巢癌完全细胞减灭术后肿瘤负担、手术时机和复杂性的预后影响的多变量分析。
Gynecol Oncol. 2020 Sep;158(3):614-621. doi: 10.1016/j.ygyno.2020.06.495. Epub 2020 Jul 22.
10
When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.当少即是多时:新辅助化疗后晚期卵巢癌间隔减瘤术的微创与剖腹手术比较。
J Minim Invasive Gynecol. 2019 Jul-Aug;26(5):902-909. doi: 10.1016/j.jmig.2018.09.765. Epub 2018 Sep 18.

引用本文的文献

1
Minimally invasive surgery in advanced and recurrent ovarian cancer: current evidence and future directions.晚期和复发性卵巢癌的微创手术:当前证据与未来方向
Curr Opin Oncol. 2025 Sep 1;37(5):478-486. doi: 10.1097/CCO.0000000000001162. Epub 2025 Jun 5.
2
The role of minimally invasive surgery in gynaecological cancer: an overview of current trends.微创手术在妇科癌症中的作用:当前趋势概述
Facts Views Vis Obgyn. 2024 Mar;16(1):23-33. doi: 10.52054/FVVO.16.1.005.
3
Editorial: Minimally invasive surgery in gynecology oncology: current trends and controversies.
社论:妇科肿瘤学中的微创手术:当前趋势与争议
Front Med (Lausanne). 2024 Jan 4;10:1353534. doi: 10.3389/fmed.2023.1353534. eCollection 2023.
4
Feasibility of laparoscopic Visceral-Peritoneal Debulking (L-VPD) in patients with stage III-IV ovarian cancer: the ULTRA-LAP trial pilot study.腹腔镜内脏腹膜减瘤术(L-VPD)治疗 III-IV 期卵巢癌患者的可行性:ULTRA-LAP 试验初步研究。
J Gynecol Oncol. 2024 Mar;35(2):e14. doi: 10.3802/jgo.2024.35.e14. Epub 2023 Oct 16.
5
A single institution's experience with minimally invasive surgery for ovarian cancer, and a systematic meta-analysis of the literature.单中心卵巢癌微创手术经验,并对文献进行系统的荟萃分析。
Int J Clin Oncol. 2023 Jun;28(6):794-803. doi: 10.1007/s10147-023-02320-2. Epub 2023 Apr 28.
6
Updates on fluorescent probes and open-field imaging methods for fluorescence-guided cytoreductive surgery for epithelial ovarian cancer: A review.荧光探针和开放式荧光成像方法在卵巢上皮性癌荧光引导细胞减灭术中的研究进展:综述。
BJOG. 2022 Nov;129 Suppl 2(Suppl 2):50-59. doi: 10.1111/1471-0528.17332.